BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17419976)

  • 1. Other mucoactive agents for cystic fibrosis.
    Bye PT; Elkins MR
    Paediatr Respir Rev; 2007 Mar; 8(1):30-9. PubMed ID: 17419976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucoactive agents for airway mucus hypersecretory diseases.
    Rogers DF
    Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacologic approach to airway clearance: mucoactive agents.
    Rubin BK
    Respir Care; 2002 Jul; 47(7):818-22. PubMed ID: 12088552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucolytics in cystic fibrosis.
    Henke MO; Ratjen F
    Paediatr Respir Rev; 2007 Mar; 8(1):24-9. PubMed ID: 17419975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care?
    Bilton D; Stanford G
    Curr Opin Pulm Med; 2014 Nov; 20(6):601-6. PubMed ID: 25221855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.
    Boogaard R; de Jongste JC; Merkus PJ
    Pediatr Pulmonol; 2007 Nov; 42(11):989-1001. PubMed ID: 17902149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the efficacy of mucoactive aerosol therapy.
    Fuloria M; Rubin BK
    Respir Care; 2000 Jul; 45(7):868-73. PubMed ID: 10926385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucolytics, expectorants, and mucokinetic medications.
    Rubin BK
    Respir Care; 2007 Jul; 52(7):859-65. PubMed ID: 17594730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacologic approach to airway clearance: mucoactive agents.
    Rubin BK
    Paediatr Respir Rev; 2006; 7 Suppl 1():S215-9. PubMed ID: 16798570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epithelium as a target for therapy in cystic fibrosis.
    Thelin WR; Boucher RC
    Curr Opin Pharmacol; 2007 Jun; 7(3):290-5. PubMed ID: 17475561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucus structure and properties in cystic fibrosis.
    Rubin BK
    Paediatr Respir Rev; 2007 Mar; 8(1):4-7. PubMed ID: 17419972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucoactive drugs and multiple applications in pulmonary disease therapy.
    Hocquigny A; Hugerot H; Ghanem R; Haute T; Laurent V; Cogulet V; Montier T
    Eur J Pharm Biopharm; 2024 Jan; 194():110-117. PubMed ID: 38048888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis.
    Amirav I; Cohen-Cymberknoh M; Shoseyov D; Kerem E
    Paediatr Respir Rev; 2009 Jun; 10(2):58-62. PubMed ID: 19410203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches.
    Puchelle E; de Bentzmann S; Zahm JM
    Respiration; 1995; 62 Suppl 1():2-12. PubMed ID: 7792436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Other medications for aerosol delivery.
    Rubin BK
    Paediatr Respir Rev; 2006; 7 Suppl 1():S76-9. PubMed ID: 16798603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational use of mucoactive medications to treat pediatric airway disease.
    Linssen RSN; Ma J; Bem RA; Rubin BK
    Paediatr Respir Rev; 2020 Nov; 36():8-14. PubMed ID: 32653467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled mannitol for the treatment of cystic fibrosis.
    Hurt K; Bilton D
    Expert Rev Respir Med; 2012 Feb; 6(1):19-26. PubMed ID: 22283575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for airway surface dehydration as the initiating event in CF airway disease.
    Boucher RC
    J Intern Med; 2007 Jan; 261(1):5-16. PubMed ID: 17222164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing clinical trials to evaluate mucus clearance therapy.
    Rubin BK
    Respir Care; 2007 Oct; 52(10):1348-58; discussion 1358-61. PubMed ID: 17894903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled hypertonic saline as a therapy for cystic fibrosis.
    Elkins MR; Bye PT
    Curr Opin Pulm Med; 2006 Nov; 12(6):445-52. PubMed ID: 17053496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.